S-1/A: Omada Health Files for IPO to Fuel Growth in Virtual Chronic Care Market

Omada Health, Inc. has filed an S-1/A registration statement for its initial public offering of 7,500,000 shares of common stock, with an anticipated price range of $18.00 to $20.00 per share, aiming to raise approximately $133.2 million for general corporate purposes and potential acquisitions.

Summary

• Omada Health, Inc. is offering 7,500,000 shares of its common stock in an initial public offering, with an anticipated price range of $18.00 to $20.00 per share.
• The company expects to raise approximately $133.2 million in net proceeds from the IPO (or $154.1 million if underwriters exercise their option in full), which will be used for general corporate purposes, including working capital, operating expenses, capital expenditures, and potential acquisitions or debt repayment.
• Omada Health provides virtual care programs for chronic conditions such as prediabetes, diabetes, hypertension, and musculoskeletal (MSK) conditions, having served over 1 million members since launch and with 679,000 total members as of March 31, 2025.
• Revenue increased by 38% from $122.8 million in 2023 to $169.8 million in 2024, and by 57% from $35.1 million in Q1 2024 to $55.0 million in Q1 2025.
• The company reported net losses of $67.5 million in 2023 and $47.1 million in 2024, and $19.0 million in Q1 2024 and $9.4 million in Q1 2025, with an accumulated deficit of $453.4 million as of March 31, 2025.
• Customer retention averaged over 90% for the year ended December 31, 2024, and the net dollar retention rate was 128% for the same period.
• A one-for-three reverse stock split was effected on May 27, 2025, prior to the offering.

Sentiment

Score: 6

Explanation: The company shows strong revenue growth, high customer retention, and positive clinical outcomes, indicating a robust core business and market acceptance. However, it has a consistent history of significant net losses and negative operating cash flows, with a large accumulated deficit, raising concerns about profitability and long-term financial sustainability without continued capital raises. The IPO is a necessary step to fund ongoing operations and growth, but the inherent risks of a rapidly evolving and competitive market, regulatory changes, and reliance on key partners temper the overall positive operational performance.

Positives

• Strong revenue growth: 38% increase from $122.8 million in 2023 to $169.8 million in 2024, and 57% increase from $35.1 million in Q1 2024 to $55.0 million in Q1 2025.
• High customer retention: Over 90% average customer retention rate for the year ended December 31, 2024.
• Strong net dollar retention: 128% for the year ended December 31, 2024, indicating significant expansion within existing customer base.
• Significant member base: Over 1 million members enrolled since launch, with 679,000 total members as of March 31, 2025.
• High member engagement: Over 55% of cardiometabolic members engaged monthly after one year, and over 50% after two years in 2024; average engagement of over 30 times per month in the first year.
• Proven clinical outcomes: 29 published, peer-reviewed studies demonstrating clinical and economic impact across its multi-condition platform.
• Industry accreditations: Full recognition from CDC Diabetes Prevention Recognition Program, ADCES accreditation for Diabetes program, NCQA accreditation for type 2 Diabetes and combined Diabetes/Hypertension programs, and URAC Telehealth accreditation for MSK program.
• Multi-condition platform: Addresses significant comorbidities (e.g., 74% of diabetes patients also have hypertension, 58% of diabetes patients have MSK conditions), simplifying care for members and contracting for customers.
• GLP-1 Care Tracks: Initial results show Enhanced GLP-1 Care Track members achieved 28% greater weight loss at week 16 and improved health behaviors (12% increase in weigh-ins, 22% more healthy meals, 27% more physical activity) compared to less engaged members.
• Post-GLP-1 discontinuation support: Members in the GLP-1 Care Track maintained weight lost (average -0.1% change) 16 weeks after discontinuation, with 84% gaining less than 4% of weight.
• Customer satisfaction: Over 90% average customer satisfaction rate for program implementation and customer success in 2024, with a Net Promoter Score of 70 as of March 2025.
• Operational efficiencies: 32% increase in total members per coach from 2023 to 2024 due to strategic efficiency initiatives and supporting technologies.
• Strong employee engagement: Overall engagement score of 78% and health coach engagement of 81% as of October 2024, with low voluntary attrition rates (9% overall, 8% for health coaches) as of December 31, 2024.

Negatives

• History of net losses: Incurred net losses of $67.5 million in 2023, $47.1 million in 2024, $19.0 million in Q1 2024, and $9.4 million in Q1 2025.
• Accumulated deficit: Reached $453.4 million as of March 31, 2025.
• Negative cash flow from operations: Used $49.7 million in 2023, $34.2 million in 2024, $20.6 million in Q1 2024, and $16.1 million in Q1 2025 in operating activities.
• Dependence on limited customers/channel partners: Top five health plan and PBM partners accounted for 68% of revenue in 2023, 69% in 2024, 67% in Q1 2024, and 73% in Q1 2025.
• Seasonality in business: Higher new member enrollment and associated costs in Q1 and Q2 lead to lower gross margins in those quarters.
• Reliance on third-party suppliers: Dependence on a limited number of suppliers for devices, cellular connectivity, and complementary healthcare services, posing risks if suppliers fail or cannot meet demand.
• Potential for increased costs as a public company: Expects significant additional legal, accounting, and other expenses.
• Identified material weaknesses in internal control over financial reporting.

Risks

• Limited operating history and challenges in effectively managing rapid growth.
• Inability to achieve or maintain profitability in the future.
• Failure of programs to achieve and maintain market acceptance.
• The market for virtual care programs is new, rapidly evolving, and increasingly competitive, making demand difficult to forecast.
• Competition from existing or potential competitors, some with greater resources, could materially and adversely affect the business.
• Competitive solutions or technological breakthroughs for chronic conditions or technological developments may adversely affect demand for programs.
• Business relies on the growth and success of customers and channel partners (health plans, PBMs), which are difficult to predict and affected by factors outside of the company's control.
• Decreases in the number of individuals covered by customers or the number of programs they cover could lead to declining member enrollment and revenue.
• Revenue depends on member engagement and the clinical outcomes/cost savings of offerings; failure to achieve these could materially and adversely affect the business.
• Significant upfront costs incurred in establishing and expanding relationships with customers and channel partners may not be recovered if relationships are not maintained or grown.
• Significant upfront costs in establishing relationships with members; failure to maintain member engagement over time could prevent cost recovery.
• Potential for licensed physical therapists to be characterized as employees, leading to increased costs and liabilities.
• Disruption of service at third-party data centers and hosting providers (e.g., Amazon Web Services) or SaaS companies could interrupt program delivery.
• Dependence on a limited number of third-party suppliers for devices, cellular device connectivity, and complementary healthcare services.
• Reliance on international supply chain exposes the company to foreign operational and political risks (e.g., tariffs, trade disputes, health crises).
• Seasonality in business may cause fluctuations in financial results.
• Failure to develop widespread brand awareness cost-effectively or widespread negative media coverage could harm the business.
• Inability to develop and release new programs/services or successful enhancements to existing programs/platform could materially and adversely affect the business.
• Risks associated with the use of AI and machine learning, including a changing regulatory landscape, inaccurate/biased recommendations, data privacy concerns, and competition.
• Failure to attract and retain senior leadership and key clinical, scientific, and technology employees.
• Reliance on a direct sales force; inability to maintain or expand it could impede growth.
• A decline in the prevalence of employer-sponsored healthcare could have a material adverse effect.
• Long and unpredictable sales and implementation cycles make sales and revenue difficult to predict.
• Failure to offer high-quality support for customers, channel partners, and members may adversely affect relationships.
• Risks related to credit card and debit card payments, including compliance and fraud.
• Operating in a highly regulated industry; changes in regulations or implementation of existing regulations could affect operations.
• Use and disclosure of personal information, including health information, is subject to federal and state privacy and security laws (e.g., HIPAA, CCPA); non-compliance could result in significant liability or reputational harm.
• Failure to comply with federal and state healthcare regulatory laws (e.g., Anti-Kickback Statute, Stark Law, False Claims Act) could lead to penalties.
• The U.S. Food and Drug Administration (FDA) may modify its enforcement policies, potentially subjecting software applications to extensive regulatory requirements.
• Dependence on relationships with affiliated professional entities (Physera Physical Therapy Group, PC); disruption or violation of state laws prohibiting corporate practice of physical therapy or fee splitting could adversely affect the business.
• Potential for medical liability claims, which could incur significant expenses not covered by insurance.
• Subject to legal and arbitration proceedings that may prevent business activities or require additional costs.
• Failure to comply with the FCPA, economic and trade sanctions regulations, and similar laws could subject the company to penalties.
• Changes in the regulation of the Internet could adversely affect the business.
• Legislative or regulatory healthcare reforms or reductions in government spending may make it more difficult and costly to produce, market, and distribute programs profitably.
• Applicability of sales, use, and other tax laws or regulations is uncertain, potentially leading to additional tax liability and penalties.
• Cash deposits with financial institutions exceed insured limits, posing a risk in case of bank failure.
• Changes in accounting principles or their interpretation by FASB could impact the consolidation of revenues derived from Physera Physical Therapy Group, PC.
• Investors in this offering will experience immediate and substantial dilution.
• Need for additional capital to support business growth, which might not be available on favorable terms or at all, and may dilute existing stockholders.
• Principal stockholders and management own a significant percentage of stock, enabling them to exert significant control.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• Provisions in charter documents and under Delaware law could discourage a takeover.
• Claims for indemnification by directors, officers, and other employees or agents may reduce available funds.
• Exclusive forum provisions in charter documents could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• The market price of common stock may be volatile.
• If securities or industry analysts do not publish research or issue adverse opinions, stock price and trading volume could decline.
• Engaging in acquisitions or strategic transactions or partnerships may increase capital requirements, dilute stockholders, cause debt, or subject the company to other risks.
• Economic uncertainties or downturns could disproportionately affect demand for programs and negatively impact the business.

Future Outlook

Omada Health plans to continue focusing on long-term growth of its core business, selectively investing in platform, program, and operational enhancements. The company monitors customer and channel partner needs and is positioned to respond organically or through partnerships and potential acquisitions. It expects GLP-1 Care Tracks to accelerate growth due to increased industry focus on GLP-1s. The company also plans to evaluate new ways to optimize outreach strategies using AI and machine learning. While currently focused on the U.S., international expansion is a long-term consideration.

Management Comments

• "Our mission is to bend the curve. Our hope is that, one day, tomorrow's epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada." Sean Duffy, Co-Founder & CEO.
• "We deliver unrivaled virtual care between doctors' visits through a simple, elegant, and seamless experience for both members and buyers."
• "We believe human relationships and empathy are fundamental drivers of sustainable behavior change."
• "We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale."
• "We believe that our customer satisfaction rates are strong and reflect the value of our services to customers."
• "We believe these engagement rates to be positive and to demonstrate the attractiveness of our program to members."
• "We believe the long-term behavior change promoted by a lifestyle modification program can improve and extend the benefits of GLP-1 medications, can help to counter the drawbacks like loss of muscle mass, and can help benefits leaders justify near-term increases in prescription drug expense."
• "We believe that our deep clinical underpinning and track record of peer-reviewed research, together with these independent recognitions and accreditations, are key differentiators in a market with many consumer-focused programs."
• "We believe no single competitor offers a broad, effective multi-condition platform at our scale and across the condition areas we address."
• "We believe that certain of our competitors rely more on technology-led support or reactive human care, as opposed to the proactive, human-led care that we supply, and that our large supporting body of peer-reviewed clinical evidence differentiates us from our competitors."
• "We believe our innovative approach to pricing—offering models that charge only for members who enroll and engage rather than at a population level—is valuable to employers and directly contributes to the sales success we have experienced."
• "We believe our proven outcomes and value proposition will resonate with these buyers similar to how they have resonated within our core markets."

Industry Context

The U.S. healthcare system faces a significant epidemiological crisis with over 156 million Americans suffering from chronic conditions, costing $3.8 trillion annually. Traditional encounter-based care models are inefficient for chronic needs, leaving patients without sufficient support between doctor's visits. Many digital health solutions have fallen short by underestimating human-led relationships, offering one-dimensional care, lacking personalization, or ignoring clinical evidence. Omada positions itself with a "Between-Visit Care" model, combining human-led clinical care with technology ("Compassionate Intelligence") to address multiple comorbid conditions (prediabetes, diabetes, hypertension, MSK). The rise of GLP-1 therapies presents both a challenge (high cost, potential weight regain upon discontinuation) and an opportunity for Omada, as FDA labels guide concurrent behavioral and lifestyle treatment plans, which Omada's GLP-1 Care Tracks aim to provide. The industry trend is moving towards integrated, multi-condition solutions to streamline vendor management for employers and health plans, a trend Omada is capitalizing on.

Comparison to Industry Standards

• Omada's Diabetes and combined Diabetes and Hypertension programs were the first type 2 diabetes programs to be awarded NCQA's Population Health Program accreditation in March 2021, distinguishing them from primary competitors like Hello Heart Inc., Lark Technologies, Inc., Livongo (via Teladoc Health, Inc.), Onduo LLC, Vida Health, Inc., and Virta Health Corp.
• Omada's MSK program was the first to be awarded URAC's Telehealth accreditation in August 2023, differentiating it from competitors like Hinge Health, Inc. and SWORD Health, Inc.
• A 2020 study on Omada for Prevention & Weight Health conducted by Cigna Healthcare showed an average return on investment (ROI) for employers of 1.7:1 at one year and 2.7:1 at two years.
• Omada's simulated average gross healthcare savings per member at three years are $3,128 for Prevention & Weight Health, $3,947 for Diabetes, and $3,138 for Hypertension, which the company believes is consistent with customer expectations for savings realization in two to three years.
• Simulated average gross healthcare savings for Omada for MSK are $1,116 $1,523 per person per year.
• Omada's retrospective analysis of GLP-1 users showed that members meaningfully engaged in Omada and on a GLP-1 achieved an average of 1.7 times the weight loss compared with those on a GLP-1 who were relatively less engaged, contrasting with studies showing significant weight regain after GLP-1 discontinuation without lifestyle support.
• Omada's average customer satisfaction rate of over 90% and Net Promoter Score of 70 (March 2025) indicate strong performance relative to general industry benchmarks for customer satisfaction.
• The company's 32% increase in total members per coach from 2023 to 2024, while maintaining comparable 6-month weight loss outcomes, suggests efficiency improvements in care delivery.
• Monthly app downloads for Omada's cardiometabolic programs have trended favorably compared to competitors like Hello Heart, Livongo Health, Hinge Health, Lark Health, Vida Health, and Onduo since 2022.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings or claims that, if determined adversely, would individually or in the aggregate have a material adverse effect on its business, operating results, cash flows, or financial condition.
• Delta Dental of California and affiliates, a dental insurance carrier for employees, was impacted by a security incident in May 2023 due to a vulnerability in third-party software (MOVEit), compromising certain employee personal information, but did not materially impact Omada's business or operations.
• Change Healthcare, an insurance claims processing vendor, experienced a cyberattack in February 2024, forcing the shutdown of its claims processing systems; Omada does not believe this materially affected its business, operations, or data.

Related Party Transactions

• Commercial arrangements exist with affiliates of The Cigna Group, which beneficially owns more than 5% of Omada's outstanding capital stock through Cigna Ventures, LLC.
• Payments from affiliates of The Cigna Group to Omada under Cigna Group Customer Agreements were $39.2 million (2022), $63.3 million (2023), $89.9 million (2024), and $42.8 million (since January 1, 2025).
• Payments from Omada to affiliates of The Cigna Group under Administrative Services Agreements were $4.3 million (2022), $5.6 million (2023), $8.6 million (2024), and $2.1 million (since January 1, 2025).
• Payments from Omada to affiliates of The Cigna Group for employee health benefits under Benefits Agreements were $6.0 million (2022), $7.5 million (2023), $8.6 million (2024), and $3.7 million (since January 1, 2025).
• Holders of approximately 39.4 million shares of common stock (including Cigna Ventures, LLC and other significant stockholders) are entitled to registration rights under an amended and restated investors rights agreement.
• The amended and restated voting agreement and the right of first refusal and co-sale agreement, involving certain directors, executive officers, and significant stockholders, will terminate upon the consummation of the IPO.

Stakeholder Impact

• Shareholders: Potential for dilution from the IPO and future capital raises; returns will depend on stock price appreciation as no dividends are planned; significant control by principal stockholders and management; exposure to stock price volatility.
• Employees: Continued employment opportunities; participation in new equity compensation plans (2025 Plan, ESPP); potential for increased compensation and benefits; benefits from a remote-first and values-driven company culture.
• Customers (Employers, Health Plans, PBMs, Health Systems): Access to a multi-condition virtual care platform designed to improve health outcomes and generate cost savings for their covered populations; benefit from flexible, engagement-based pricing models and streamlined integration.
• Members: Access to personalized, human-led virtual care for chronic conditions, including connected devices, peer support groups, medication support (e.g., GLP-1 Care Tracks), and behavioral health support, aiming for improved health outcomes (weight loss, A1C reduction, blood pressure control, MSK pain/function improvement).
• Suppliers/Vendors: Continued business relationships with limited third-party suppliers for devices, connectivity, and complementary services, with potential for increased demand.
• Creditors: Existing debt obligations under the MidCap Credit Agreement ($31.0 million outstanding as of March 31, 2025); IPO proceeds may be used for debt repayment, potentially improving creditworthiness.

Next Steps

• Complete the initial public offering and list common stock on the Nasdaq Global Market under 'OMDA'.
• Continue to focus on long-term growth of the core business.
• Selectively invest in areas that enhance the platform, programs, or operations.
• Monitor the needs of customers and channel partners to respond organically or through partnerships and potential acquisitions.
• Evaluate new ways to optimize outreach strategies using AI and machine learning.
• Potentially expand programs internationally in the long term.
• Remediate identified material weaknesses in internal control over financial reporting.
• Comply with increased legal, accounting, and reporting expenses as a public company.
• Potentially draw down the Second Tranche of the MidCap Term Facility by December 31, 2025, subject to revenue conditions.
• Settle RSUs and manage sell-to-cover transactions starting September 2025.

Key Dates

Recommendation

Keywords

Virtual care, Chronic disease management, Digital health, Prediabetes, Diabetes, Hypertension, Musculoskeletal, MSK, GLP-1, Weight management, Healthcare technology, Telehealth, SEC filing, IPO, S-1/A, Omada Health